Trial
NCT06022224
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
ImmunityBio, Inc.
Collaborators
—
Condition
COVID-19
Intervention
hAd5-S-Fusion+N-ETSD
Why stopped
There were no participants enrolled into Phase 3 portion of the study because the study was prematurely terminated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-07